MMWR Recomm Rep. 1992 Feb 7;41(RR-1):1-10.
This supplementary statement provides information on and recommendations for the use of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). One such vaccine was recently licensed, ACEL-IMMUNE.* This vaccine is licensed for use only as the fourth and fifth doses of diphtheria, tetanus, and pertussis vaccination; it is not licensed for the initial three-dose series in infants and children, regardless of age. At least one other DTaP product is anticipated to be licensed in the future for use as the fourth and fifth doses. The current Immunization Practices Advisory Committee (ACIP) statement on diphtheria, tetanus, and pertussis issued August 8, 1991, gives general recommendations on pertussis prevention, including the use of whole-cell pertussis vaccines for primary and booster vaccination (1).
本补充声明提供了关于白喉、破伤风类毒素和无细胞百日咳疫苗(DTaP)使用的信息及建议。一种此类疫苗ACEL-IMMUNE*最近已获许可。该疫苗仅被许可用作白喉、破伤风和百日咳疫苗接种的第四剂和第五剂;无论年龄大小,均未被许可用于婴幼儿的前三剂基础免疫接种。预计未来至少还有一种DTaP产品将被许可用作第四剂和第五剂。1991年8月8日发布的现行免疫实践咨询委员会(ACIP)关于白喉、破伤风和百日咳的声明给出了预防百日咳的一般建议,包括使用全细胞百日咳疫苗进行基础免疫和加强免疫(1)。